ZYMEWORKS INC. (ZYME) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$42.18M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$47.12M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$22.11M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$674.00K; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$42.18M | (m) | $4.59M | (m) | $0.00* | -$31.95M* | (m) | (m) | (m) | -$273.00K |
| 2026-03-31 | Reported | (m) | -$47.12M | (m) | $2.41M | (m) | $216.00K | -$45.72M | (m) | (m) | (m) | -$2.19M |
| 2025-09-30 | Reported | (m) | -$22.11M | (m) | $27.61M | (m) | $410.00K* | -$31.41M* | (m) | (m) | (m) | $1.34M |
| 2025-06-30 | Reported | (m) | -$674.00K | (m) | $48.73M | (m) | $514.00K* | $12.07M* | (m) | (m) | (m) | -$186.00K |
| 2025-03-31 | Reported | (m) | -$25.61M | (m) | $27.11M | (m) | $16.00K | -$3.41M | (m) | (m) | (m) | $496.00K |
| 2024-09-30 | Reported | (m) | -$34.20M | (m) | $16.00M | (m) | $899.00K* | -$5.88M* | (m) | (m) | (m) | $226.00K |
| 2024-06-30 | Reported | (m) | -$42.89M | (m) | $19.24M | (m) | $593.00K* | -$24.99M* | (m) | (m) | (m) | $68.00K |
| 2024-03-31 | Reported | (m) | -$37.80M | (m) | $10.03M | (m) | $185.00K | -$37.67M | (m) | $32.04M | (m) | $75.00K |
| 2023-09-30 | Reported | (m) | -$33.24M | (m) | $16.51M | (m) | $930.00K* | -$42.67M* | (m) | $32.77M | (m) | $1.11M |
| 2023-06-30 | Reported | (m) | -$54.11M | (m) | $7.00M | (m) | $802.00K* | -$6.40M* | (m) | $39.41M | (m) | $1.65M |
| 2023-03-31 | Reported | (m) | -$27.28M | (m) | $35.58M | (m) | $386.00K | -$83.19M | (m) | $45.91M | (m) | $1.39M |
| 2022-09-30 | Reported | (m) | -$50.36M | (m) | $2.63M | (m) | $981.00K* | -$73.02M* | (m) | $37.10M | (m) | -$29.00K |
| 2022-06-30 | Reported | (m) | -$65.82M | (m) | $5.44M | (m) | $2.66M* | -$54.82M* | (m) | $56.02M | (m) | -$9.00K |
| 2022-03-31 | Reported | (m) | -$72.69M | (m) | $1.92M | (m) | $4.16M | -$55.41M | (m) | $62.51M | (m) | -$74.00K |
| 2021-09-30 | Reported | (m) | -$60.96M | (m) | $4.39M | (m) | (m) | (m) | (m) | $49.89M | (m) | $764.00K |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$92.55M | (m) | $105.97M | (m) | $1.52M | -$33.01M | (m) | (m) | (m) | $1.38M |
| 2024-12-31 | Reported | (m) | -$137.11M | (m) | $76.30M | (m) | $1.99M | -$110.06M | (m) | (m) | (m) | $6.08M |
| 2023-12-31 | Reported | (m) | -$138.05M | (m) | $76.01M | (m) | $2.47M | -$118.32M | (m) | $143.62M | (m) | -$568.00K |
| 2022-12-31 | Reported | (m) | $130.53M | (m) | $412.48M | (m) | $8.15M | $144.11M | (m) | $208.60M | (m) | $10.89M |
| 2021-12-31 | Reported | (m) | -$215.63M | (m) | $26.68M | (m) | $12.40M | -$192.45M | (m) | $199.75M | (m) | -$516.00K |
| 2020-12-31 | Reported | (m) | -$187.47M | (m) | $38.95M | (m) | $4.31M | -$151.40M | (m) | $171.20M | (m) | $429.00K |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |